< back

ADIPOA2

Autologous Adipose-Derived Mesenchymal Stromal Cells in the Treatment of Mild to Moderate Osteoarthritis

A phase IIb, prospective, multicentre, double-blind, triplearm, randomized versus placebo trial, to assess the efficacy of a single injection of either 2 or 10 x 106 autologous adipose derived mesenchymal stromal cells (ASC) in the treatment of mild to moderate osteoarthritis (OA) of the knee, active and unresponsive to conservative therapy for at least 12 months.

Population: adult | Intervention type: therapeutic medicinal product